MiMedx Group, Inc.

Equities

MDXG

US6024961012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
6.27 ^USD	+0.40%		-0.32%	-28.51%

Mar. 27	MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products	MT
Mar. 27	MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit	DJ

Mimedx Group, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 03, 2021 at 05:14 pm EDT

MiMedx Group, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 68.165 million compared to USD 53.647 million a year ago. Operating loss was USD 410,000 compared to USD 5.856 million a year ago. Net loss was USD 1.779 million compared to USD 8.466 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.08 a year ago. For the half year, sales was USD 128.132 million compared to USD 115.383 million a year ago. Operating loss was USD 7.262 million compared to USD 19.600 million a year ago. Net loss was USD 10.161 million compared to USD 13.287 million a year ago. Basic loss per share from continuing operations was USD 0.12 compared to USD 0.12 a year ago.

Latest news about MiMedx Group, Inc.

MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products	Mar. 27	MT
MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit	Mar. 27	DJ
MiMedx Group, Inc. Provides Update on AXIOFILL Request for Designation from FDA	Mar. 27	CI
MiMedx Group to Buy Distribution Rights for TELA Bio's Wound Care Product	Mar. 20	MT
MiMedx Launches E-Commerce Platform	Mar. 13	MT
Mimedx Introduces E-Commerce and Account Management Platform	Mar. 13	CI
Lake Street Starts MiMedx Group With Buy Rating, $12 Price Target	Mar. 07	MT
MiMedx Group, Inc. Announces Appointment of New Independent Directors	Mar. 04	CI
Mizuho Securities Raises Price Target on MiMedx to $14 From $13, Maintains Buy Rating	Mar. 01	MT
Spectral AI Names Peter Carlson Chief Executive Officer; Reaffirms 2024 Preliminary Revenue Guidance	Mar. 01	MT
Transcript : MiMedx Group, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (MDXG) MIMEDX GROUP Posts Q4 Revenue $86.8M, vs. Street Est of $85.2M	Feb. 28	MT
Earnings Flash (MDXG) MIMEDX GROUP Reports Q4 EPS $0.04, vs. Street Est of $0.06	Feb. 28	MT
MiMedx Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
MiMedx Group, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing	Jan. 22	CI
MiMedx reports US FDA warning letter for Axiofill, shares drop	Dec. 29	RE
Stocks to Watch : MiMedx Group, Nokia	Dec. 29	DJ
MiMedx says US FDA's warning letter for Axiofill not related to safety	Dec. 29	RE
MiMedx Group Gets FDA Warning Letter on Axiofill Classification	Dec. 29	DJ
MiMedx Group Converts Series B Preferred Stock to Common Stock, Adds 30 Million Shares	Dec. 28	MT
Spectral AI Names Peter M. Carlson CFO	Dec. 19	MT
Mizuho Securities Adjusts MiMedx Price Target to $12 From $14, Maintains Buy Rating	23-10-31	MT
MiMedx Group Swings to Q3 Profit, Revenue Rises; Shares Fall After Hours	23-10-30	MT
Transcript : MiMedx Group, Inc., Q3 2023 Earnings Call, Oct 30, 2023	23-10-30

Chart MiMedx Group, Inc.

Duration

Period

More charts

Company Profile

MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for MiMedx Group, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.27 USD

Average target price

12.44 USD

Spread / Average Target

+98.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Medical Devices

	1st Jan change	Capi.
MIMEDX GROUP, INC.	-28.51%	922M
NIBEC CO., LTD.	-20.60%	129M
COLLPLANT BIOTECHNOLOGIES LTD.	-7.82%	61.39M
KIM FOREST ENTERPRISE CO., LTD.	+6.64%	60.85M
NOVACYT	+14.87%	60.15M
BONUS BIOGROUP LTD.	+0.60%	51.57M

Bio Medical Devices